<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245254</url>
  </required_header>
  <id_info>
    <org_study_id>2329</org_study_id>
    <nct_id>NCT04245254</nct_id>
  </id_info>
  <brief_title>GutMe!: IBS and Collagen Protein Powder an Interventional Study</brief_title>
  <acronym>GutMe</acronym>
  <official_title>GutMe!: IBS and Collagen Protein Powder an Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProofPilot</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProofPilot</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we would like to understand how or if a food-based supplement affects gut&#xD;
      symptoms such as bloating, stomach cramps and irregular bowel habits. Through using a digital&#xD;
      symptom tracking app for a few weeks, you may just learn more about exactly what is&#xD;
      triggering your symptoms!&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm interventional study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All participants receive one brand of collegen protien powder</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in self-reported IBS symptoms</measure>
    <time_frame>Baseline, Week 4 and Week 10</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Irritable Bowel</condition>
  <condition>Irrit</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study. Receives collagen protein powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Collagen Protien Powder</intervention_name>
    <description>Collegen Protein Powser</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  US based&#xD;
&#xD;
          -  self report bloating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  vegan or vegetarian diet&#xD;
&#xD;
          -  suffering from any skin disorders&#xD;
&#xD;
          -  kidney disease&#xD;
&#xD;
          -  treated medical issues&#xD;
&#xD;
          -  glutamine sensitivity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women are more affected by IBS than men.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ProofPilot (Virtual Study: https://p.proofpilot.com)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are currently no plans to make PID available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

